Short Interest in Exicure, Inc. (NASDAQ:XCUR) Decreases By 28.5%

Exicure, Inc. (NASDAQ:XCUR) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 62,840 shares, a decline of 28.5% from the January 29th total of 87,833 shares. Approximately 2.1% of the company’s shares are sold short. Based on an average trading volume of 33,193 shares, the short-interest ratio is currently 1.9 days. Based on an average trading volume of 33,193 shares, the short-interest ratio is currently 1.9 days. Approximately 2.1% of the company’s shares are sold short.

Exicure Stock Performance

XCUR opened at $3.74 on Friday. Exicure has a 1 year low of $3.10 and a 1 year high of $15.91. The firm has a 50 day moving average price of $4.98 and a 200 day moving average price of $4.88. The company has a market cap of $23.82 million, a PE ratio of -1.01 and a beta of 4.10.

Analyst Ratings Changes

XCUR has been the subject of several research analyst reports. Wall Street Zen raised shares of Exicure to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Exicure presently has a consensus rating of “Sell”.

Insiders Place Their Bets

In other news, major shareholder Sangsangin Investment & Securi sold 433,332 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $8.71, for a total transaction of $3,774,321.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 52.80% of the company’s stock.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.